Oxford Biomedica PLC Holding(s) in Company (2334J)
April 01 2015 - 11:43AM
UK Regulatory
TIDMOXB TIDMAV.
RNS Number : 2334J
Oxford Biomedica PLC
01 April 2015
For filings with the FCA
include the annex
For filings with issuer exclude
the annex
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i)
---------------------------------------------------------------------------------------------------------------
1. Identity of the issuer or Oxford BioMedica plc
the underlying issuer
of existing shares to which
voting rights are
attached: (ii)
----------------------------------------------------------------- --------------------------------------------
2 Reason for the notification (please tick the appropriate
box or boxes):
---------------------------------------------------------------------------------------------------------------
An acquisition or disposal of voting rights
-------------------------------------------------------------------- -----------------------------------------
An acquisition or disposal of qualifying financial
instruments which may result in the acquisition
of shares already issued to which voting rights
are attached
-------------------------------------------------------------------- -----------------------------------------
An acquisition or disposal of instruments with
similar economic effect to qualifying financial
instruments
-------------------------------------------------------------------- -----------------------------------------
An event changing the breakdown of voting rights
-------------------------------------------------------------------- -----------------------------------------
Other (please
specify):
----------------------------------------------------------- ------- -----------------------------------------
3. Full name of person(s) Aviva plc & its subsidiaries
subject to the
notification obligation:
(iii)
------------------------------------------------------------- ------------------------------------------------
4. Full name of shareholder(s) Registered Holder:
(if different from 3.):(iv)
BNY Norwich Union Nominees
Limited 7,731,682*
Chase (GA Group) Nominees
Limited 197,907,307*
*denotes direct interest
Chase (GA Group) Nominees
Limited 16,452,188
Chase Nominees Limited 6,527,175
Vidacos Nominees Limited 1,471,192
------------------------------------------------------------- ------------------------------------------------
5. Date of the transaction 31 March 2015
and date on
which the threshold is
crossed or
reached: (v)
------------------------------------------------------------- ------------------------------------------------
6. Date on which issuer 1 April 2015
notified:
------------------------------------------------------------- ------------------------------------------------
7. Threshold(s) that is/are 7% to 8% Change at Direct
crossed or Interest Level
reached: (vi, vii)
------------------------------------------------------------- ------------------------------------------------
8. Notified details:
--------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares (viii, ix)
--------------------------------------------------------------------------------------------------------------
Class/type Situation previous Resulting situation after
of to the triggering the triggering transaction
shares transaction
if possible
using
the ISIN
CODE
--------------- ------------------------------- ------------------------------------------------------------
Number Number Number Number of % of voting
of of of voting rights (x)
Shares Voting shares rights
Rights
--------------- --------------- -------------- ------------ -------------------------- ------------------
Direct Direct Indirect Direct Indirect
(xi) (xii)
--------------- --------------- -------------- ------------ ------------- ----------- ------- ---------
Ordinary
Shares
GB00066458157 240,000,000 240,000,000 250,089,544 205,638,989 44,450,555 8.01% 1.73%
--------------- -------------- ------------ ------------- ----------- ------- ---------
B: Qualifying Financial Instruments
--------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
--------------------------------------------------------------------------------------------------------------
Type of Expiration Exercise/ Number of voting % of voting
financial date Conversion rights that rights
instrument (xiii) Period (xiv) may be
acquired if
the
instrument
is
exercised/
converted.
--------------- --------------- -------------- ---------------------------------------- ------------------
C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments (xv, xvi)
-----------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
-----------------------------------------------------------------------------------------------
Type of financial Exercise Expiration Exercise/ Number of voting % of voting
instrument price date Conversion rights instrument rights (xix,
(xvii) period refers to xx)
(xviii)
------------------ --------- ----------- ------------ ------------------- ----------------
Nominal Delta
------------------ --------- ----------- ------------ ------------------- -------- ------
Total (A+B+C)
-----------------------------------------------------------------------------------------------
Number of voting rights Percentage of voting rights
-------------------------------------------------------- -------------------------------------
250,089,544 9.74%
-------------------------------------------------------- -------------------------------------
9. Chain of controlled undertakings through which the
voting rights and/or the
financial instruments are effectively held, if applicable:
(xxi)
------------------------------------------------------------------------------
The voting rights are managed and controlled by Aviva
Investors Global Services Limited, with the following
chain of controlled undertakings:-
Aviva Investors Global Services Limited:
* Aviva plc (Parent Company)
* Aviva Group Holdings Limited (wholly owned subsidiary
of Aviva plc)
* Aviva Investors Holdings Limited (wholly owned
subsidiary of Aviva Group Holdings Limited)
* Aviva Investors Global Services Limited (wholly owned
subsidiary of Aviva Investors Holdings Limited)
Proxy Voting:
------------------------------------------------------------------------------
10. Name of the proxy holder: See Section 4
--------------------------------------------- -------------------------------
11. Number of voting rights proxy
holder will cease
to hold:
--------------------------------------------- -------------------------------
12. Date on which proxy holder will
cease to hold
voting rights:
--------------------------------------------- -------------------------------
13. Additional information: Figures are based on a total
number of voting rights of
2,567,098,228 as per the
Company's Total Voting Rights
Announcement of 3 March 2015.
--------------------------------------------- -------------------------------
14. Contact name: Tim Watts, Chief Financial
Officer, Oxford BioMedica
--------------------------------------------- -------------------------------
15. Contact telephone number: +44 (0) 1865 783 000
--------------------------------------------- -------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLUAOVRVWASRAR
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2023 to Apr 2024
